Elizabeth Vigeant’s Post

In this edition of the New Medicines, Novel Insights newsletter, Paul Bridges chats with clinical experts from Parexel and Health Advances about the critical decision points in the pre-clinical phase that can ultimately determine the success of your product. Learn how these experts are helping biotech companies reduce risk by advocating for better coordination among departments, with a clear patient focus, at the earliest stages. Create success by planning for it ✅ Read the full article below and subscribe for our latest #NovelInsights #ParexelBiotech #ClinicalDevelopment #EarlyPhase #DrugDevelopment

In this edition of the New Medicines, Novel Insights newsletter, Paul Bridges chats with clinical experts from Parexel and Health Advances about the critical decision points in the pre-clinical phase that can ultimately determine the success of your product. Learn how these experts are helping biotech companies reduce risk by advocating for better coordination among departments, with a clear patient focus, at the earliest stages. Create success by planning for it ✅ Read the full article below and subscribe for our latest #NovelInsights #ParexelBiotech #ClinicalDevelopment #EarlyPhase #DrugDevelopment

𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝗔𝗜 Explore AI’s pivotal role in revolutionizing the drug discovery, diagnostics, treatment personalization, and clinical efficiency segments of the healthcare industry. Our Ingenious team of Life science experts has recognized the top eight AI applications driving the healthcare sector. We help enterprises strategically integrate these AI-powered applications and stay resilient in the ferociously transformative phase of the industry. Talk to our expert Ayushi Singh to explore the key insights into the healthcare sector by emailing us: [email protected] To know more, visit us: www.iebrain.com #drugdiscovery #drugdevelopment #aihealthcare #biotechnology #biomedical #precisionmedicine #futureproofingbusinesses

🚀 Project Strawberry: Implications on Pharma OpenAI's latest initiative, Project Strawberry, is set to transform our industry: - Accelerate drug discovery by an order of magnitude - Revolutionize our understanding of complex diseases - Design patient-centric clinical trials with unprecedented precision I've prepared a sythesis of this groundbreaking development. Swipe/download to explore the potential impact on our sector. Thoughts on how this could reshape our industry? Let's discuss. #PharmaTech #AIInnovation #FutureOfHealthcare

Today I am proud to announce Lifebit’s data catalog has reached over 100M patients’ data, covering health and multi-omic data across +200 conditions, from >30 of our valued global data partners. This represents the world’s most diverse clinical-genomics data resource, and has the potential to be truly transformative for our pharma partners to advance precision medicine and generate discoveries that save lives. With data serving as the new productivity driver for the pharmaceutical industry at Lifebit our teams are working tirelessly to revolutionize healthcare by providing researchers with unparalleled access to diverse datasets crucial for understanding diseases and developing life-saving treatments. This achievement could not have been possible without the dedication of our team and our collaborations with leading healthcare providers, research institutions and population genomics initiatives across the globe. Together, we are paving the way for a future where access to biomedical data is never again an obstacle to curing diseases. Read our press release for more details: https://bit.ly/3uPLMu7 #PrecisionMedicine #Biotech #DataInnovation #Lifebit #datasaveslives

Client Success Amplified! Through our Hub of Biotherapeutic Intelligence, we're all about turning potential into reality. Highlighting the momentum and message from JPM, we have been taking strategic strides in the world of biotherapeutics to set the foundation. Our significant hubs in North America and Europe are the driving force behind our mission to create an expansive global network and clusters of excellence. What sets us apart? • Our IPA team, with a full continuum offering in the areas of therapeutic, therapeutic companion and diagnostic antibodies, protein production and AI integrated intelligence. We don't just collaborate with clients; we co-create success. • We collaborate closely with our clients, strategically designing programs to optimize clinical roadmaps, effectively becoming an extension of their team. • Our commitment to innovation knows no bounds. With our global reach and expertise, we're designed at our core to optimize and reduce costs and time associated with bringing antibodies to clinical trials. Here's to our clients who are achieving remarkable milestones with us. Your success is what drives us! Join the journey of biotherapeutic excellence with us: https://bit.ly/46XqDLE #HubOfBiotherapeuticIntelligence #Antibodies #Biotechnology #TechBio #AI #ArtificialIntelligence #ProteinProduction #Innovation #DrugDiscovery #GlobalNetwork

🌟  Transforming Health: One Byte at a Time! 🌟 At xBxBio, we're all about making a significant impact on health with cutting-edge science personalized just r you!  Imagine a world where treatments are tailored just like your favorite coffee! That's what xBxBio will do with diseases like cancer and Alzheimer's—making medicines that fit your unique genetic makeup perfectly. 💡 Why does this matter? Because personalized treatment means more effective care and, importantly, fewer side effects, reassuring you that treatments truly work for YOU! Our vision? A world where your medical treatment is as unique as you are, created faster, cheaper, and safer, thanks to our intelligent platforms that learn and adapt. 🚀 Join www.xbxbio.com on this incredible journey, where every discovery brings us closer to a healthier tomorrow. Learn more about how xBxBio is redefining medicine at www.xbxbio.com. #HealthTech #Innovation #PersonalizedMedicine #Biotechnology #DigitalHealth #PatientCare #SustainableHealthcare #DrugDevelopment #MedicalResearch #TechForGood #AIinHealthcare #MachineLearning #CloudComputing #DataScience #FutureOfHealthcare #EthicalTech #SmartHealthcare #HealthcareDisruption #VirtualHealth #Genomics #Bioinformatics #xTechForHealth #TransformHealthcare

I'm delighted to share my blog post, 'Current Climate: Decoding Therapeutics Financing', which is part of our series on medicine commercialisation.

Last week, Daniel Jamieson gave a brilliant talk at #AIdrivenDrugDiscovery in Boston on leveraging the power of cause-and-effect data in a GenAI world. Whether or not you were able to attend, you should check out his guide on what it takes to cultivate a world-class GenAI organisational strategy in biopharma >> https://lnkd.in/eAdUxpbJ In this short clip from the start of Dan's talk, he sets the scene by reminding us of what is important to keep in mind when thinking about GenAI technologies -- what part they can play to help us fail fast and make better decisions for a faster and better drug development pipeline.

The second blog in the 'Unlocking the Secrets of Medicine Commercialisation’ series is now live. Current Climate: Decoding Therapeutics Financing by Dr Tim Newton, Senior Market Analyst at MDC, discusses how we can use the data to help inform policymakers and create a more robust architecture for our sector going forward. 🔗 Read here: https://hubs.li/Q02zNXr20 Tim N. #Therapeutics #Financing #DrugDiscovery #MDCconnects